Bristol Myers Squibb BMY announced that the European Commission has approved the combination of its blockbuster ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

Raymond Y. Huang, MD, Ph.D., of the Department of Radiology at Brigham and Women's Hospital, is the corresponding author of a ...

Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Ovarian Cancer.

A paper published in the Journal of Clinical Oncology, titled "Comparative Analysis of Intracranial Response Assessment ...

The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...

In this prespecified interim analysis, nivolumab plus ipilimumab was compared to chemotherapy. Overall, 303 patients who had not previously received systemic treatment were randomly assigned to ...

Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Dedifferentiated Liposarcoma.

In this prespecified interim analysis, nivolumab plus ipilimumab was compared to chemotherapy. Overall, 303 patients who had not previously received systemic treatment were randomly assigned to ...

By binding to CTLA4, which is a key negative regulator of T-cell activation, ipilimumab (developed by Medarex in conjunction with Bristol-Myers Squibb) acts to potentiate the immune response ...

Raymond Y. Huang, MD, Ph.D., of the Department of Radiology at Brigham and Women’s Hospital, is the corresponding author of a paper published in the Journal of Clinical Oncology, “Comparative Analysis ...